To the full analysis
Pharmaron Beijing stock: growth
300759.SZPharmaron Beijing reported $2.11B in revenue for fiscal 2025, up 14.8% on the prior year, up 22.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
29.9%
per year from 2014 to 2025, per share 16%
Earnings (Annual rate)
48.8%
per year from 2014 to 2025, per share 32.8%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 22.4% | 28.7% | 29.9% |
| Revenue per share | 4.2% | 13.6% | 16.0% |
| Earnings | 7.3% | 36.5% | 48.8% |
| Earnings per share | −8.7% | 14.2% | 32.8% |
| Free cash flow | 10.7% | no data | no data |
| Free cash flow per share | −5.7% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $118.54M | $3.15M | −$10.47M |
| 2015 | $169.17M | $11.07M | −$6.21M |
| 2016 | $245.08M | $26.53M | −$122.93M |
| 2017 | $344.04M | $34.62M | −$57.35M |
| 2018 | $436.11M | $49.94M | $14.44M |
| 2019 | $563.44M | $82.06M | $27.59M |
| 2020 | $769.86M | $175.82M | $49.9M |
| 2021 | $1.12B | $249.09M | −$5.22M |
| 2022 | $1.54B | $206.14M | −$121.03M |
| 2023 | $1.73B | $240.11M | −$16.76M |
| 2024 | $1.84B | $268.94M | $80.38M |
| 2025 | $2.11B | $249.53M | $82.78M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Mar 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.